A randomized, open-label, single-dose, 3-period crossover, pharmacokinetic study designed to compare the systemic des-ciclesonide exposure of OMNARIS (ciclesonide) nasal spray, ciclesonide HFA [hydrofluoroalkane] nasal aerosol, and orally inhaled ciclesonide.

Trial Profile

A randomized, open-label, single-dose, 3-period crossover, pharmacokinetic study designed to compare the systemic des-ciclesonide exposure of OMNARIS (ciclesonide) nasal spray, ciclesonide HFA [hydrofluoroalkane] nasal aerosol, and orally inhaled ciclesonide.

Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Ciclesonide (Primary) ; Ciclesonide (Primary)
  • Indications Allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Jun 2011 Actual end date (Apr 2008) added as reported by ClinicalTrials.gov.
    • 18 Mar 2008 Results presented at AAAAI in 2008
    • 17 Mar 2008 Status changed to completed in accordance with Sepracor media release 9086472, which states that safety and pharmacokinetic results were presented at the 2008 annual meeting of the American Academy of Allergy Asthma and Immunology (AAAAI).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top